Related Experiment Video
Updated: Aug 29, 2026

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
Published on: June 15, 2019
Sepsis and disseminated intravascular coagulation
Marcel Levi1, Evert de Jonge, Tom van der Poll
1Department of Internal Medicine/Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. m.m.levi@amc.uva.nl
Insights
Sepsis frequently causes coagulation disorders like disseminated intravascular coagulation (DIC), leading to organ failure. Novel therapies targeting coagulation activation show promise in managing sepsis-induced hemostatic abnormalities.
Area of Science:
- Critical Care Medicine
- Hematology
- Pathophysiology
Background:
- Sepsis commonly induces hemostatic abnormalities, ranging from mild changes to severe disseminated intravascular coagulation (DIC).
- DIC plays a crucial role in sepsis-induced microvascular dysfunction and organ failure.
- Coagulation activation in sepsis can lead to depletion of platelets and clotting factors, resulting in bleeding complications.
Purpose of the Study:
- To review recent insights into the pathogenetic mechanisms of sepsis-induced DIC.
- To discuss novel preventive and therapeutic strategies for managing coagulation derangements in sepsis.
Main Methods:
- Review of clinical and experimental studies on sepsis and hemostasis.
- Analysis of pathogenetic mechanisms including the tissue factor/factor VIIa route, impaired anticoagulant pathways (antithrombin III, protein C), and fibrin degradation.
- Evaluation of supportive strategies targeting coagulation activation.
Main Results:
- Thrombin generation involves the extrinsic pathway and is exacerbated by suppressed inhibitory mechanisms.
- High levels of plasminogen activator inhibitor-1 (PAI-1) impair fibrinolysis, promoting intravascular fibrin deposition.
- Experimental and initial clinical studies suggest benefits from inhibiting coagulation activation or restoring anticoagulant pathways.
Conclusions:
- Understanding sepsis-induced DIC pathogenesis has led to new therapeutic approaches.
- Strategies inhibiting coagulation activation or restoring physiological anticoagulation show potential.
- Inhibition of tissue factor or administration of antithrombin/activated protein C are promising supportive therapies.
Abstract:
Sepsis almost invariably leads to hemostatic abnormalities, ranging from insignificant laboratory changes to severe disseminated intravascular coagulation (DIC). There is compelling evidence from clinical and experimental studies that DIC is involved in the pathogenesis of microvascular dysfunction and contributes to organ failure. In addition, the massive and ongoing activation of coagulation, may deplete platelets and coagulation factors, which may in turn cause bleeding. Recent insights into important pathogenetic mechanisms that may lead to DIC have resulted in novel preventive and therapeutic approaches to patients with sepsis and a derangement of coagulation. Thrombin generation proceeds via the (extrinsic) tissue factor/factor VIIa route and simultaneously occurring depression of inhibitory mechanisms, such as antithrombin III and the protein C system. Also, impaired fibrin degradation, due to high circulating levels of PAI-1, contributes to enhanced intravascular fibrin deposition. Supportive strategies aimed at the inhibition of coagulation activation may be justified on theoretical grounds and have been found to be beneficial in experimental and initial clinical studies. These strategies comprise inhibition of tissue factor-mediated activation of coagulation or restoration of physiological anticoagulant pathways, by means of the administration of antithrombin concentrate or recombinant human activated protein C.
More Related Videos
Related Concept Videos
Acute Inflammation III: Local and Systemic Effects
Hemorrhagic Stroke ll: Pathophysiology
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Anticoagulant Drugs: Low-Molecular-Weight Heparins
